Replies to post #86160 on Biotech Values

[DewDiligence]

TEVA:

so this new [Copaxone] formulation would be the basis of an ANDA because of the differences between it and the original copaxone?

No, Teva will submit “low volume” Copaxone as a supplemental NDA. (As the owner of Copaxone, Teva would not ever be the applicant for a Copaxone ANDA.)